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Cancer stem cells (CSCs) drive solid tumor formation. In this issue of Cancer Cell, Zhao and colleagues in-
dentify the calcium channel a2d1 subunit as a new functional hepatocellular carcinoma (HCC) CSC
biomarker, which is vital for CSC biology as blocking a2d1 in combination with doxorubicin treatment hinders
HCC tumor formation.Hepatocellular carcinoma (HCC) ac-
counts for 90% of primary liver cancers
and is the third most common cause of
cancer-related deaths worldwide (Ed-
wards et al., 2010). Unlike most other
carcinomas, where mutations in specific
oncogenes or tumor suppressors drive
tumor initiation and progression, the
majority of HCCs are multifactorial and
primarily due to infections with hepatitis
B virus (HBV) or hepatitis C virus (HCV).
However, worldwide cases of nonviral
HCC are on the rise due to growing
numbers of patients with metabolic liver
diseases (Alberti et al., 2005; Van Thiel
and Ramadori, 2011). This multi-causality
makes identification and subsequent
targeting of a common HCC-specific
alteration or even a cell-of-origin virtually
impossible. Fortunately, where con-
sensus does exist is in the concept that
the majority of HCC arise from a subpop-
ulation of cancer cells referred to as tu-
mor-initiating cells (TICs) or cancer stem
cells (CSCs) (Majumdar et al., 2012).
Thus, identifying and therapeutically tar-
geting these cells represents a more
feasible approach for treating HCC
regardless of the underlying cause.
CSCs are believed to possess stem
cell-like properties such as unlimitedself-renewal, exclusive in vivo tumorige-
nicity, and subsequent generation of
differentiated progeny recapitulating the
parental tumor phenotype (Figure 1). Evi-
dence for their existence in several solid
tumors has been experimentally demon-
strated (reviewed in Hermann et al.,
2010). For HCC, cells expressing diverse
markers such as CD133, CD13, CD24,
CD90, and EpCAM as well as cells
defined as the side population have all
been demonstrated to bear CSC charac-
teristics. Apparently, the utility of these
different markers across established cell
lines and primary tumors varies signifi-
cantly, and their suitability for therapeutic
targeting has not been extensively
evaluated. Therefore, the identification of
markers, preferably a single marker, for
efficient isolation of CSCs from the com-
plex tumor cellular environment across
different HCC tissues is still critically
needed.
In this issue of Cancer Cell, Zhao et al.
(2013) report that HCC CSCs can be spe-
cifically isolated with a new antibody
(1B50-1) identified using awhole-cell sub-
tractive immunization approach that rec-
ognizes the isoform 5 of the cell surface
calcium channel a2d1 subunit. 1B50-1
binds a subpopulation of HCC cells, here-after termed a2d1+ cells, exhibiting stem
cell-like properties, such as increased
invasiveness, expression of stem cell-
associated genes (OCT4, SOX2, NANOG,
and BMI1), increased self-renewal, and
the ability to give rise to both a2d1+ and
a2d1– cells. More importantly, the authors
showed that subcutaneously injected
a2d1+ cells from cell lines and primary
HCC tumors were more tumorigenic in
NOD/SCID mice compared to their a2d1–
counterparts. Although the increased
tumorigenic potential of a2d1+ cells was
evident with as little as 103 cells, limiting
dilution assays (injection with less than
100 cells were not performed) revealed
that not all a2d1+ cells were tumorigenic
(TIC frequency in primary cases: 1 in 458
[748-281]), and higher numbers of a2d1–
cells were also capable of forming tumors
(TIC frequency: 1 in 1,957 [3,785-1,012])
(calculated from Table 1 in Zhao et al.,
2013). Therefore, a2d1+ cells from primary
tumors were enriched for CSCs 4-fold.
Unlike many normal tissues where a
stringent unidirectional hierarchy and
strict balanced asymmetric division pre-
serve tissue integrity (Jan and Jan,
1998), data in solid tumors are generally
not as clear cut. On the one hand, this
might be related to our still limited abilityl 23, April 15, 2013 ª2013 Elsevier Inc. 431
Figure 1. The CSC Concept
HCC, likemany other solid tumors, is composed of a heterogeneous population of cells that contain CSCs.
Although the process of hepatocarcinogenesis is multi-causal and multi-factorial, HBV and HCV infection,
as well as metabolic liver diseases are the primary mediators of HCC. During tumor initiation, liver progen-
itor cells, hepatocytes, or circulating bone marrow-derived cells are believed to suffer genetic and epige-
netic changes, which, together with a deregulation of the microenvironment (e.g., chronic inflammation
and cirrhosis), eventually give rise to a distinct subpopulation of CSCs that have stem-like properties.
CSCs can survive current standard therapies, resulting in tumor recurrence and disease relapse. The
work by Zhao et al. (2013) suggests that HCC CSCs overexpress the calcium channel a2d1 subunit,
and thus targeting a2d1 (e.g., using 1B50-1), or its downstream mediators (e.g., inhibition of ERK1/2),
and in combination with standard chemotherapy may eradicate HCC.
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organization of solid tumors. Indeed,
Zhao et al. (2013) also showed a clear hi-
erarchical organization within the a2d1+
sub-population for HCC, demonstrating
that a2d1+ cells additionally expressing
CD133, CD13, or EpCAM were even
more tumorigenic in vivo. However, these
marker combinations remain challenging,
because a2d1+ cells that are negative for
the second marker and vice versa also
result in a moderate enrichment for CSC,
and double negative populations are still
not void of CSC activity (Figure 1H in
Zhao et al., 2013). On the other hand,
the border between tumorigenic CSCs
and their nontumorigenic progenies might
be more dynamic than in normal tissue,
and intermediate progenitors in cancer
tissue might be capable of replenishing
tumorigenic CSCs. The latter should be
more stringently tested in vitro and in vivo
at the single cell level in order to identify
the specific subset of a2d1+ cells with
exclusive tumorigenic potential as well
as to thoroughly evaluate the possibility
that a subset of a2d1– cells is capable of432 Cancer Cell 23, April 15, 2013 ª2013 Elsreplenishing a2d1+ CSCs. Furthermore,
we also should not underestimate the
important role of the tumor microenviron-
ment that could dramatically alter a cell’s
in vivo tumorigenic potential (Lonardo
et al., 2012; Quintana et al., 2008).
While these studies remain pending,
Zhao et al. (2013) further showed that in
86 paired HCC and paracancerous tissue
samples, a2d1+ cells could be found
not only in the majority of primary HCC
samples but also in many of the corre-
sponding paracancerous tissues. More-
over, when sorted, only a2d1+ cells from
both the primary tumor and paracancer-
ous tissues were tumorigenic in vivo
(even though the number of tested
samples was very small) and could reca-
pitulate the parental tumor phenotype.
Interestingly, although a2d1+ staining
in the primary tumor did not correlate
with any clinicopathological factor,
a2d1+ staining in the paracancerous tis-
sue strongly correlated with cirrhosis,
quicker recurrence, and shorter survival,
supporting the potential use of a2d1+
staining in paracancerous tissue as aevier Inc.prognostic HCC biomarker. Although
the present study was not really powered
to model the multifactorial panorama
of HCC and therefore more extensive
studies are still warranted, this study
clearly supports the hypothesis that
a2d1+ cells in paracancerous tissue
represent a putative cell-of-origin for
HCC recurrence.
Next, the authors determined the func-
tion of a2d1 in HCCCSCbiology. a2d1 is a
protein component of the voltage-depen-
dent calcium channel complex, of which
there exist several types. Calcium influx
is an essential cellular process mediating
a plethora of intracellular signaling cas-
cades such as MAPK signaling. Not only
was a2d1 over-expressed in a2d1+ cells,
but also intracellular calcium concentra-
tions and calcium oscillations were higher
in a2d1+ cells and could be modulated by
1B50-1 treatment or a2d1 silencing. In
addition, ERK1/2 phosphorylation was
suppressed by a2d1 inhibition, suggest-
ing that a2d1 may potentiate HCC CSC
by activating pro-survival pathwaysmedi-
ated by MAPKs via a calcium-dependent
mechanism. Indeed, the authors show
that a2d1+ cells were also susceptible to
the ERK1/2 inhibitor U0126. Therefore,
these findings highlight not only a2d1 as
amarker amenable for HCCCSC isolation
but also a previously unappreciated role
for Ca2+ influx in CSC biology.
Finally, one of the most interesting
aspects of the present study centered
on the therapeutic potential of targeting
a2d1. Zhao et al. (2013) convincingly
demonstrate that treatment of HCC cells
with 1B50-1 or silencing of a2d1 de-
creases CSC activity via induction of
cellular apoptosis by downregulation of
BCL2 and upregulation of BAX and BAD.
Importantly, 1B50-1 not only reduced tu-
mor size and induced cell apoptosis but
also affected the CSC content, as deter-
mined by loss of a2d1+ cells and loss of
serial transplantation capacity in NOD/
SCID mice. Importantly, the effects could
be further augmented by the addition of
doxorubicin, supporting a bimodal treat-
ment approach in which CSCs and their
progenies are simultaneously targeted.
This kind of combinatorial approach
has also been proposed for other solid
tumors, such as pancreatic ductal adeno-
carcinoma (Lonardo et al., 2011), andmay
also reflect the need for blocking re-
plenishment of CSCs from their more
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these promising results, studies focusing
on the use of 1B50-1 or other agents
that target a2d1 in HCC and potentially
in other solid tumors should be exten-
sively pursued.
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